Immune-Mediated Inflammatory Diseases
ZLDPFZealand PharmaCatalyst overview
Research summary
This catalyst tracks a Phase 1a data readout for ZP9830 (Kv1.3 Channel Blocker) in Immune-Mediated Inflammatory Diseases. The expected timing is based on the latest available company guidance and may change.
02/18/26:- Positive Ph1a SAD topline in NCT06682975; MAD data and Ph1b-2a start expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.